disorder

(redirected from Myeloproliferative disorders)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

disorder

a disturbance of public order or peace. Its existence may trigger extended police powers.

References in periodicals archive ?

Elliott, "Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F," Seminars in Thrombosis and Hemostasis, vol.

Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera

Burgstaller et al., "Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders," Blood, vol.

Myeloid neoplasms with t(5;12) and ETV6-ACSL6 gene fusion, potential mimickers of myeloid neoplasm with PDGFRB rearrangement: case report with imatinib therapy and review of the literature

Since patient had past history of myeloproliferative disorder and US scan revealed an enlarged liver we organised a CT scan abdomen and pelvis liver protocol.

CAVERNOUS TRANSFORMATION OF PORTAL VEIN - A RARE CAUSE OF MASSIVE HEPATOMEGALY

According to Dameshek, true polycythemia (polycythemia vera: PV) is a chronic myeloproliferative disorder of the total bone marrow without any evidence of invasiveness, in which erythrocytosis, leukocytosis, and thrombocytosis are all simultaneously present.

Physiopathology, Etiologic Factors, Diagnosis, and course of polycythemia vera as related to therapy according to william Dameshek, 1940-1950 / William Dameshek'e (1940-1950) Gore Tedavi Actsindan Polistemia Vera'ntn Fizyopatolojisi, Etiyolojik Faktorleri, Tanisi ve Seyri

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111: 1686-9.

COLD-PCR and innovative microarray substrates for detecting and genotyping MPL exon 10 W515 substitutions

The most common causes of thrombophilia in patients with BCS are JAK2 mutation positive myeloproliferative disorders (40%), followed by factor V Leiden (6.8-31.8%) mutation and prothrombin G20210A mutation (0-.64%).

A rare case of Budd Chiari syndrome

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer.

Myeloproliferative neoplasms: an overview

18% of men in a cohort of patients seen at the center for myeloproliferative disorders of Johns Hopkins University in Baltimore, said Dr.

Women more likely to experience thrombosis

However, at least in patients with idiopathic myelofibrosis and other chronic myeloproliferative disorders, an alternative pathogenesis has been proposed.

Extramedullary hematopoiesis mimicking hepatocellular carcinoma

Chronic myeloproliferative disorders (CMPDs) are clonal haematopoietic stem cell disorders and include the BCR-ABL negative CMPDs like polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF) and chronic eosinophilic leukaemia (CEL) (1,2).

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders

Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.

CYTOPIA PROGRAM REACHES MILESTONE AT CANCER THERAPEUTICS

In these cases haemorrhage was associated with risk factors (myeloproliferative disorders, aspirin, platelet dysfunction, thrombocytopenia, obesity and disseminated intravascular coagulation) and the patients required sustained blood transfusion.